CD40 and rheumatoid arthritis: In a third study, activated macrophages of rheumatoid arthritis patients were treated with anti-TNF-α agents, which lead to decreased production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12), and decreased expression of inflammation marker (CD40), enhanced phagocytic activity as well as polarization towards M2 phenotype.